Hong Kong · Delayed Price · Currency is HKD SinoMab BioScience Company Description
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong.
Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome.
It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus.
In addition, the company is developing SM06, a humanised Anti-CD22, that is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren’s syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin’s lymphoma and autoimmune diseases.
Further, it develops Anti-CGC antibody, which is in preclinical trial to treat vitiligo and alopecia areata; and Bispecific antibody candidate (bsAb), which is in preclinical trial to treat osteoporosis.
SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Tai Po, Hong Kong.
| Country | Hong Kong |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Shui On Leung |
Contact Details
Address: No.15 Science Park West Avenue Tai Po Hong Kong | |
| Phone | 852 3426 9833 |
| Website | sinomab.com |
Stock Details
| Ticker Symbol | 3681 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | HK0000544194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shui On Leung | Founder, Chairman and Chief Executive Officer |
| Jianping Hua | Chief Financial Officer |
| Yuande Zhang | Director of Marketing |
| Dr. Lixin Zhang Auberson | Chief Medical Officer |
| Wai K Lai | Company Secretary |